生物股份：子公司获得猫传染性腹膜炎mRNA疫苗临床试验批件

Core Viewpoint - The company has received clinical trial approval for a cat infectious peritonitis mRNA vaccine, marking a significant milestone in veterinary vaccine development [1] Group 1: Company Development - The company's wholly-owned subsidiary, Jinyu Baoling, has obtained the clinical trial approval from the Ministry of Agriculture and Rural Affairs for the cat infectious peritonitis mRNA vaccine [1] - The vaccine is developed in collaboration with Beijing Hesheng Gene Technology Co., Ltd., addressing the current lack of commercialized vaccines for this disease [1] - The total research and development investment for the project amounts to approximately 6.2 million yuan [1] Group 2: Industry Context - The company is the first in the country to receive clinical approval for a veterinary nucleic acid vaccine targeting cat infectious peritonitis [1] - The development cycle for veterinary vaccine products is lengthy and carries inherent uncertainties [1]